Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
This article was originally published in The Pink Sheet Daily
Executive Summary
Full details on the pivotal RISE and RIDE trials in diabetic macular edema at ADA meeting show that the drug improves vision and halts disease progression, paving way for FDA filing this fall.
You may also be interested in...
Genentech Says Lucentis DME Product Will Ship Shortly
FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.